Provided by Tiger Trade Technology Pte. Ltd.

NKGen Biotech Inc.

0.0600
0.0000
Volume:1.00K
Turnover:60.06
Market Cap:7.84M
PE:-0.05
High:0.0600
Open:0.0600
Low:0.0600
Close:0.0600
52wk High:0.9100
52wk Low:0.0002
Shares:130.60M
Float Shares:17.66M
Volume Ratio:0.05
T/O Rate:0.01%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.2317
EPS(LYR):-1.5361
ROE:--
ROA:-93.33%
PB:-0.16
PE(LYR):-0.04

Loading ...

Company Profile

Company Name:
NKGen Biotech Inc.
Exchange:
EXPERT
Establishment Date:
2017
Employees:
26
Office Location:
3001 Daimler Street,Santa Ana,California,United States
Zip Code:
92705
Fax:
- -
Introduction:
NKGen Biotech, Inc. operates as a clinical-stage biotechnology company that focuses on the development and commercialization of autologous, allogeneic, and CAR-NK natural killer cell therapies. Its lead products include SNK01, an autologous NK cell therapy candidate treatment for neurodegenerative diseases; and SNK02, an allogeneic NK cell therapy, which is in Phase 1 clinical trials for refractory solid tumors. The company has a license agreement with NKMAX. The company was formerly known as NKMAX America, Inc. NKGen Biotech, Inc. was founded in 2017 and is headquartered in Santa Ana, California. NKGen Biotech, Inc. operates as a subsidiary of NKMAX Co., Ltd.